Metastatic Colorectal Cancer, Quality of Life
Conditions
Keywords
bevacizumab, health related quality of life
Brief summary
The primary aim of this french multicenter national study is to assess and compare time to quality of life score deterioration (targeted dimensions : global health, fatigue and emotional functionning of EORTC QLQC30 according to the first line chemotherapy associated with bevacizumab in metastatic colorectal patients.
Interventions
DRUGBevacizumab
Sponsors
Centre Hospitalier Universitaire de Besancon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* age\> 18years * metastatic colorectal cancer (non resectable) * 1st chemotherapy including bevacizuman
Exclusion criteria
* treatment contre-indication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| time to health related quality of life score deterioration (targeted dimensions of EORTC QLQC30 : global health, fatigue, emotional functioning) | 1 year | The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| INT PATSAT32 | 1 year | The EORTC IN-PATSAT32 is a 32-item satisfaction with care questionnaire to measure patients' appraisal of hospital doctors and nurses, as well as aspects of care organisation and services. It addresses technical competence, information provision, interpersonal skills, availability, waiting time, access, comfort and overall care perception |
| quality-adjusted life years (QALYs) using EQ5D | 1 year | — |
| time to health related quality of life score deterioration (non targeted dimensions of EORTC QLQC30 and CR 29) | 1 year | — |
| Progression Free Survival | 1 year | — |
| treatment preference | 1 year | — |
| Overall survival | 2 years | — |
Countries
France
Contacts
Primary ContactMarion Jacquin, Msc
Backup ContactIkram El SaaD, Msc
Outcome results
None listed